Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 785 Shares of Balchem Co. (NASDAQ:BCPC)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its position in Balchem Co. (NASDAQ:BCPC) by 20.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,030 shares of the basic materials company’s stock after selling 785 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Balchem were worth $425,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of BCPC. Cardinal Capital Management increased its position in shares of Balchem by 0.4% during the 4th quarter. Cardinal Capital Management now owns 19,539 shares of the basic materials company’s stock valued at $2,922,000 after purchasing an additional 79 shares during the last quarter. Signaturefd LLC increased its position in Balchem by 123.0% during the fourth quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock valued at $25,000 after acquiring an additional 91 shares during the last quarter. SageView Advisory Group LLC raised its stake in shares of Balchem by 2.1% in the third quarter. SageView Advisory Group LLC now owns 4,814 shares of the basic materials company’s stock valued at $597,000 after acquiring an additional 98 shares during the period. Commonwealth Equity Services LLC raised its stake in shares of Balchem by 0.7% in the third quarter. Commonwealth Equity Services LLC now owns 14,532 shares of the basic materials company’s stock valued at $1,803,000 after acquiring an additional 104 shares during the period. Finally, Advisor Partners II LLC lifted its holdings in shares of Balchem by 5.8% in the 3rd quarter. Advisor Partners II LLC now owns 2,124 shares of the basic materials company’s stock worth $263,000 after acquiring an additional 116 shares during the last quarter. 87.91% of the stock is owned by hedge funds and other institutional investors.

Balchem Trading Up 1.2 %

Shares of BCPC stock traded up $1.66 on Tuesday, reaching $145.38. 11,846 shares of the company’s stock were exchanged, compared to its average volume of 103,265. The company’s fifty day simple moving average is $152.36 and its 200 day simple moving average is $139.71. Balchem Co. has a 52 week low of $110.74 and a 52 week high of $159.52. The company has a current ratio of 2.12, a quick ratio of 1.38 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $4.69 billion, a PE ratio of 42.90, a P/E/G ratio of 4.33 and a beta of 0.71.

Balchem (NASDAQ:BCPC) last released its earnings results on Friday, February 16th. The basic materials company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.02. The business had revenue of $228.70 million for the quarter, compared to analyst estimates of $234.66 million. Balchem had a return on equity of 10.69% and a net margin of 11.77%. The business’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.66 earnings per share. As a group, analysts forecast that Balchem Co. will post 4.14 EPS for the current year.

Insider Buying and Selling at Balchem

In other news, CEO Theodore L. Harris sold 34,350 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $154.29, for a total transaction of $5,299,861.50. Following the transaction, the chief executive officer now directly owns 66,412 shares of the company’s stock, valued at $10,246,707.48. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Theodore L. Harris sold 34,350 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $154.29, for a total transaction of $5,299,861.50. Following the transaction, the chief executive officer now owns 66,412 shares of the company’s stock, valued at approximately $10,246,707.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael Robert Sestrick sold 11,100 shares of the firm’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $153.21, for a total value of $1,700,631.00. Following the transaction, the senior vice president now owns 6,736 shares in the company, valued at approximately $1,032,022.56. The disclosure for this sale can be found here. Insiders sold a total of 76,630 shares of company stock valued at $11,843,249 in the last three months. Company insiders own 1.77% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Balchem from a “hold” rating to a “buy” rating in a research report on Wednesday, February 21st.

About Balchem

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.